SCHEMBL4287322

SCHEMBL4287322

CCCCCCCCCCCOCC(O)CO

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 1.00
HTT P42858 2/20 0.69
LPAR5 Q9H1C0 4/20 0.59
PLA2G2C Q5R387 1/20 0.56
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
SPHK1 Q9NYA1 1/20 0.53
KDM4E B2RXH2 1/20 0.53
DUSP3 P51452 1/20 0.53
LMNA P02545 1/20 0.53
THRB P10828 1/20 0.52
MAPT P10636 1/20 0.52
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C19 P33261 1/20 0.50
LPAR1 Q92633 4/20 0.46
LPAR2 Q9HBW0 4/20 0.46
LPAR3 Q9UBY5 4/20 0.46
LPAR6 P43657 3/20 0.46
LPAR4 Q99677 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1965457 1.00 USP2 (1.00) USP2HTTLPAR5PLA2G2CMEN1
SCHEMBL9248716 1.00 USP2 (1.00) USP2HTTLPAR5PLA2G2CMEN1
SCHEMBL8022797 1.00 USP2 (1.00) USP2HTTLPAR5PLA2G2CMEN1
SCHEMBL116830 1.00 USP2 (1.00) USP2HTTLPAR5PLA2G2CMEN1
SCHEMBL8856104 1.00 USP2 (1.00) USP2HTTLPAR5PLA2G2CMEN1
SCHEMBL24835077 1.00 USP2 (1.00) USP2HTTLPAR5PLA2G2CMEN1
SCHEMBL932977 1.00 USP2 (1.00) USP2HTTLPAR5PLA2G2CMEN1
SCHEMBL1086330 1.00 USP2 (1.00) USP2HTTLPAR5PLA2G2CMEN1
SCHEMBL21082980 1.00 USP2 (1.00) USP2HTTLPAR5PLA2G2CMEN1
SCHEMBL38241 1.00 USP2 (1.00) USP2HTTLPAR5PLA2G2CMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12090205-B2 Poloxamer compositions with reduced sol-gel transition temperatures and methods of reducing the sol-gel transition temperature of poloxamer compositions ROCHAL TECHNOLOGIES LLC (US) 2024-09-17 US claimed
CN-116829203-A Coated medical product 亨莫特克股份公司 2023-09-29 CN claimed
CN-116710156-A Coated medical product 亨莫特克股份公司 2023-09-05 CN claimed
EP-3204037-B1 COMPOSITIONS AND KITS FOR ENZYMATIC DEBRIDEMENT AND METHODS OF USING THE SAME ROCHAL TECH LLC (US) 2022-12-07 EP claimed
CN-107106663-B Compositions and kits for enzymatic debridement and methods of use thereof 罗查尔科技有限责任公司 2022-12-06 CN claimed
EP-4051239-A1 POLOXAMER COMPOSITIONS WITH REDUCED SOL-GEL TRANSITION TEMPERATURES AND METHODS OF REDUCING THE SOL-GEL TRANSITION TEMPERATURE OF POLOXAMER COMPOSITIONS Rochal Technologies LLC (US) 2022-09-07 EP claimed
CN-114929200-A Method for lowering sol-gel transition temperature 罗查尔科技有限责任公司 2022-08-19 CN claimed
WO-2021086698-A1 METHODS FOR REDUCING THE TEMPERATURE OF SOL-GEL TRANSITIONS ROCHAL INDUSTRIES, LLC (US) 2021-05-06 WO claimed
US-20210121575-A1 Poloxamer Compositions With Reduced Sol-Gel Transition Temperatures and Methods of Reducing the Sol-Gel Transition Temperature of Poloxamer Compositions ROCHAL INDUSTRIES, LLC (US) 2021-04-29 US claimed
EP-2787985-B1 BIOCIDAL COMPOSITIONS AND METHODS OF USING THE SAME ROCHAL IND LLC (US) 2020-07-01 EP claimed
CN-107106663-A Composition and kit and its application method for enzyme debridement 罗查尔工业有限责任公司 2017-08-29 CN claimed
EP-3204037-A1 COMPOSITIONS AND KITS FOR ENZYMATIC DEBRIDEMENT AND METHODS OF USING THE SAME Rochal Industries, LLC (US) 2017-08-16 EP claimed
US-20170151314-A1 COMPOSITIONS AND KITS FOR ENZYMATIC DEBRIDEMENT AND METHODS OF USING THE SAME CRG SERVICING LLC 2017-06-01 US claimed
US-9592280-B2 Compositions and kits for enzymatic debridement and methods of using the same ROCHAL INDUSTRIES LLC (US) 2017-03-14 US claimed
US-20160199459-A1 COMPOSITIONS AND KITS FOR TREATING PRURITUS AND METHODS OF USING THE SAME CRG SERVICING LLC 2016-07-14 US claimed
WO-2016057788-A1 COMPOSITIONS AND KITS FOR ENZYMATIC DEBRIDEMENT AND METHODS OF USING THE SAME ROCHAL INDUSTRIES, LLC (US) 2016-04-14 WO claimed
US-20160101165-A1 COMPOSITIONS AND KITS FOR ENZYMATIC DEBRIDEMENT AND METHODS OF USING THE SAME CRG SERVICING LLC 2016-04-14 US claimed
US-20160101166-A1 COMPOSITIONS AND KITS FOR TREATING PRURITUS AND METHODS OF USING THE SAME CRG SERVICING LLC 2016-04-14 US claimed
US-8829053-B2 Biocidal compositions and methods of using the same ROCHAL INDUSTRIES LLP (US) 2014-09-09 US claimed
US-20130150451-A1 BIOCIDAL COMPOSITIONS AND METHODS OF USING THE SAME ROCHAL INDUSTRIES, LLP (US) 2013-06-13 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12090205-B2 Poloxamer compositions with reduced sol-gel transition temperatures and methods of reducing the sol-gel transition temperature of poloxamer compositions PAOX, HPGDS, SPTSSB USP2 706/4885HTT 2356/4885LPAR5 1253/4885
US-20210121575-A1 Poloxamer Compositions With Reduced Sol-Gel Transition Temperatures and Methods of Reducing the Sol-Gel Transition Temperature of Poloxamer Compositions PAOX, HPGDS, SPTSSB USP2 706/4885HTT 2356/4885LPAR5 1253/4885
US-20130150451-A1 BIOCIDAL COMPOSITIONS AND METHODS OF USING THE SAME GCG, BID, DGAT1 USP2 1260/4885HTT 4280/4885LPAR5 3209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.